Entera Bio Ltd. Operating Cash Flow Margin

Operating Cash Flow Margin of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating Cash Flow Margin growth rates and interactive chart.


Highlights and Quick Summary

  • Operating Cash Flow Margin for the quarter ending June 29, 2020 was -6780.77% (a 7.23% increase compared to previous quarter)
  • Year-over-year quarterly Operating Cash Flow Margin increased by 145.38%
  • Annual Operating Cash Flow Margin for 2019 was -3779.24% (a 92.9% increase from previous year)
  • Annual Operating Cash Flow Margin for 2018 was -1959.2% (a -Infinity% decrease from previous year)
  • Twelve month Operating Cash Flow Margin ending June 29, 2020 was -4314.06% (a 24.38% increase compared to previous quarter)
  • Twelve month trailing Operating Cash Flow Margin decreased by -Infinity% year-over-year
Trailing Operating Cash Flow Margin for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
-4314.06% -3468.35% -1211.82% 0.0%
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating Cash Flow Margin of Entera Bio Ltd.

Most recent Operating Cash Flow Marginof ENTX including historical data for past 10 years.

Interactive Chart of Operating Cash Flow Margin of Entera Bio Ltd.

Entera Bio Ltd. Operating Cash Flow Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -6780.77% -6323.81%
2019 -3141.18% -2763.33% -2870.27% 0.0% -3779.24%
2018 -470.4% 0.0% 0.0% 0.0% -1959.2%
2017 0.0% 0.0%

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.